Advanced Breast Cancer Clinical Trials

20 studies are recruiting for advanced breast cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

   This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growt…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado

   Locations

   62 in total

   Run by

   BeOne Medicines

   See if you can join NCT06120283 on ClinicalTrials.gov

2. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

   First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Comprehensive Cancer Center, Duarte, California

   Locations

   44 in total

   Run by

   TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

   See if you can join NCT06625775 on ClinicalTrials.gov

3. A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

   The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH) within each cohort.

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   Genesis Cancer and Blood Institute, Hot Springs, Arkansas

   Locations

   23 in total

   Run by

   TerSera Therapeutics LLC

   See if you can join NCT07310420 on ClinicalTrials.gov

4. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

   This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Banner MD Anderson Cancer Center, Gilbert, Arizona

   Locations

   231 in total

   Run by

   Relay Therapeutics, Inc.

   See if you can join NCT06982521 on ClinicalTrials.gov

5. Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

   A study to investigate camizestrant in combination with atirmociclib in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Research Site, St Louis, Missouri

   Locations

   6 in total

   Run by

   AstraZeneca

   See if you can join NCT07427394 on ClinicalTrials.gov

6. Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

   The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Gilbert, Arizona

   Locations

   306 in total

   Run by

   AstraZeneca

   See if you can join NCT06380751 on ClinicalTrials.gov

7. Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

   Background: Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help. It stops cancer cells from growing and spreading further and possibly shrink cancer l…

   Stage

   Phase 1

   Ages

   12 to 120

   Site

   University of Kansas, Fairway, Kansas

   Locations

   2 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04222413 on ClinicalTrials.gov

8. Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer

   The purpose of this study is to test whether four different supportive care programs can reduce fatigue in women with advanced or metastatic breast cancer who are receiving a medication called a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) alongwith endocrine therapy with or without a…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Miami, Miami, Florida

   Locations

   3 in total

   Run by

   University of Miami

   See if you can join NCT06123988 on ClinicalTrials.gov

9. A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer

   The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced or metastatic HR positive, HER2 negative breast cancer who have progressed on standard of care options can affect patients survival. The main questions it aims to answer are: * will the TheraBio…

   Stage

   Not phased

   Ages

   22 and older

   Site

   Karmanos Cancer Institute at McLaren Bay Region, Bay City, Michigan

   Locations

   8 in total

   Run by

   Barbara Ann Karmanos Cancer Institute

   See if you can join NCT07227831 on ClinicalTrials.gov

10. Decision Support Tool for Patients With Advanced Breast Cancer

    The goal of this pilot study is to understand and improve the shared decision-making process between people with advanced breast cancer and their providers regarding their care and treatment. As part of this study, the researchers will evaluate a decision support tool called COAST that was designed…

    Stage

    Not phased

    Ages

    18 and older

    Site

    NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York

    Locations

    3 in total

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT07635147 on ClinicalTrials.gov

11. Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

    The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal g…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Baptist Health Herbert Wertheim Cancer Institute, Miami, Florida

    Locations

    3 in total

    Run by

    Reshma L. Mahtani, D.O.

    See if you can join NCT06263543 on ClinicalTrials.gov

12. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Highlands Oncology Group, Springdale, Arkansas

    Locations

    45 in total

    Run by

    Stemline Therapeutics, Inc.

    See if you can join NCT06638307 on ClinicalTrials.gov

13. A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

    The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This stu…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California

    Locations

    13 in total

    Run by

    Pfizer

    See if you can join NCT07318805 on ClinicalTrials.gov

14. Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

    This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Los Angeles, Los Angeles, California

    Locations

    5 in total

    Run by

    Regor Pharmaceuticals Inc.

    See if you can join NCT07524322 on ClinicalTrials.gov

15. A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

    The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    21 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT06997029 on ClinicalTrials.gov

16. Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

    Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Hoag Memorial Hospital Presbyterian, Newport Beach, California

    Locations

    15 in total

    Run by

    Ensem Therapeutics

    See if you can join NCT06993844 on ClinicalTrials.gov

17. Engage Psychosocial Intervention for Cancer Symptoms

    The goal of this clinical trial is to test the efficacy a new psychosocial symptom management intervention called ENGAGE for patients with Stage IV breast, prostate, lung, or colorectal cancer. Participants will be randomized to ENGAGE or a Supportive Care intervention. Patient-reported outcomes wi…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Duke Cancer Network, Durham, North Carolina

    Run by

    Duke University

    See if you can join NCT06555588 on ClinicalTrials.gov

18. Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

    The purpose of this study is to learn if certain drug combinations are effective treatments for patients with advanced ER+/HER2- who have previously been treated with palbociclib, ribociclib, or abemaciclib.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

    Run by

    Dartmouth-Hitchcock Medical Center

    See if you can join NCT05933395 on ClinicalTrials.gov

19. The COMPASSION Study

    The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between participants and caregivers and oncology care teams.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT06507930 on ClinicalTrials.gov

20. First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

    This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, cataly…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Arizona Cancer Center, Tucson, Arizona

    Locations

    37 in total

    Run by

    Relay Therapeutics, Inc.

    See if you can join NCT05216432 on ClinicalTrials.gov